MediciGlobal
Trailblazers in Patient Recruitment and Retention
MediciGroup® aka MediciGlobal was founded in 1991 by pharmaceutical veteran Elizabeth Moench. The company laid the foundation for recruitment methodologies that are commonly practiced worldwide by recruitment practitioners today.
Medici Global
MediciGlobal’s forward thinking technology, feasibility planning, online outreach media and approaches to patient recruitment and retention revolutionized every aspect of the patient recruitment-retention process, and its corporate mantra of putting patients first has been at the cornerstone of its success.
In July 2015, MediciGroup was acquired by BioClinica, and in August 2020, BioClinica sold the former Medici team and its site network (CCBR) to the global CRO PPD. It now operates as AES (Accelerated Enrollment Solutions).
Industry Firsts
MediciGlobal is renowned for many industry firsts. Listed below are some of its major ones:
MediciGlobal Leaders Today
Having been at the forefront of the pharmaceutical industry for more than 35 years, Elizabeth Moench developed numerous disruptive technologies and methodologies aimed at streamlining inefficiencies that radically changed pharmaceutical industry practices. These included bringing prescription medicines directly to patients, with the launch of the first direct to consumer (DTC) advertising campaign in 1983 for prescription only ibuprofen. She started the first company dedicated to streamlining patient enrollment for clinical trials (MediciGobal in 1991), she established the process of predictive enrollment modelling, first published in Applied Clinical Trials in 1993, led the first company to use Facebook for clinical trial recruitment; establishing patient communities to promote clinical research opportunities, and the first company to develop online pre-screening technologies to save time at trial sites to focus time on patients more likely to meet clinical protocol requirements.
The insight she accumulated in these roles, and the resulting frustrations she witnessed around the delays to data lock due to missing patients, laid the concept for WeFindPatients, a novel service in the industry.
More than a decade ago, she established a service called L2FU that worked with global pharmaceutical companies to locate clinical trial patients in more than 60 countries. That experience enabled her to identify technological opportunities to streamline patient tracing. Today, Liz has spearheaded the technological backbone of the company WeFindPatients, an online global decentralized platform specifically designed to optimize the patient search process. The platform brings together sites, researchers, investigative agents, and clinical trial teams, in a secure environment to protect patient confidentiality. The platform is FDA CFR Part 11, HIPAA and EU GDPR compliant. www.WeFindPatients.com
Former Global VP Marketing
Nick Halkitis pioneered micromarketing techniques aimed at finding niche patient populations in niche therapeutic areas, in a manner that optimized limited budgets and delivered results ahead of schedule. At a time when Facebook was emerging as a formidable social media platform, Mr. Halkitis was the first to advise Facebook on the use of its platform for clinical trials. In his advisory role, he visited with Facebook teams in London UK, Dublin Ireland, New York, and Austin Texas. Nick Halkitis continues to own and manage, and impressive portfolio of digital assets focused in healthcare and clinical trials. Today, his micromarketing expertise extends beyond clinical trials to include other niche and competitive markets in Tourism, travel and fashion. Today, he heads marketing firm Syncoset. www.syncoset.com
